Diabetes Obes Metab: Relationship between the risk of pneumonia in patients with type 2 diabetes with DPP-4 inhibitors.

There are !---- concerns that dipeptide peptide asse 4 inhibitors (DPP-4i) may increase the risk of pneumoniaIn a recent study published in the journal Diabetes Obesity and Metabolism, researchers analyzed observational data and clinical trials to explore whether using DPP-4i could alter the risk of pneumoniaThe researchers identified diabetics in the Veneto Regional Administrative Database and conducted a preference score match (PSM) between new users of DPP-4 inhibitors and other new users of oral sugar reduction drugs (OGLM)The researchers used the Cox Scale Risk Model to compare the hospitalization rates of pneumonia between matching queues and repeated the same analysis using a database of local diabetes clinicsThe researchers retrieved similar observational studies from the literature for meta-analysis and reported on trials of pneumonia incidence in patients with a random group using DPP-4 inhibitors and placebo/positive control drugsIn the regional database, 6,495 patients were matched in each group, and the hospitalization rate for new patients with DPP-4 inhibitors was lower than for new patients using other OGLM (HR was 0.76; 95% C.Iwas 0.61-0.95)In the outpatient database, 867 patients were matched in each group, and the hospitalization rate for new patients with DPP-4 inhibitors decreased significantly (HR was 0.65; 95% C.Iwas 0.41-1.04)A meta-analysis of the observational study showed a significant reduction in the overall risk of hospitalization for pneumonia in DPP-4i users (RR was 0.81; 95% C.Iwas 0.65-1.01)A meta-analysis of randomized controlled trials showed that DPP-4i had no overall effect on pneumonia risk (RR 1.06; 95% C.Iwas 0.93-1.20)In terms of pneumonia risk, the use of DPP-4i in diabetic patients is considered safe